nach oben

Erschienen in:

01.10.2019 | Systematic Review

A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss

verfasst von: Vincenzo Di Nunno, Veronica Mollica, Matteo Brunelli, Lidia Gatto, Riccardo Schiavina, Michelangelo Fiorentino, Matteo Santoni, Rodolfo Montironi, Anna Caliò, Albino Eccher, Michele Milella, Guido Martignoni, Eugenio Brunocilla, Francesco Massari

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Context

9p loss appears a reliable and promising marker able to differentiate specific categories of patients with renal cell carcinoma associated with a worse prognosis.

Objective

The aim was to systematically evaluate relative risk of death, cancer-specific survival (CSS) and disease-free survival (DFS) among patients harboring 9p loss.

Evidence Synthesis

We found a total of 92 potentially relevant articles focused on the detection of 9p loss in patients with renal cell carcinoma and clinical outcomes of this population. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines were employed to carry out this work. Fourteen studies resulted to be eligible for this analysis; 11 of these reported data on 5-year overall survival, six on CSS and four on DFS. An increased risk of death has been observed in patients harboring 9p loss (pooled relative risk of 3.965; 95% confidence interval [CI] 2.647–5.940, p < 0.001). Similarly, worse CSS (hazard ratio [HR] 6.776; 95% CI 3.824–12.009; p < 0.001) and DFS (HR 2.914; 95% CI 1.245–6.819; p = 0.014) have been observed in this population. Heterogeneity was significant in survival analysis, while no significant heterogeneity was observed in the CSS and DFS analyses.

Conclusions

Patients harboring chromosome 9p loss have worse clinical outcomes in terms of overall survival, CSS and DFS.

Nur mit Berechtigung zugänglich

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.PubMedCrossRef

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–9.CrossRef

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.CrossRef

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(12):3698.PubMedCrossRef

Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26(3):319–30.PubMedPubMedCentralCrossRef

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur Urol. 2019;75(1):100–10.PubMedCrossRef

Salgia M, Adashek J, Bergerot P, Pal SK. Non-clear cell renal cell carcinoma: current management and best practice. Kidney Cancer. 2017;1(2):99–105.PubMedPubMedCentralCrossRef

Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528.PubMedPubMedCentralCrossRef

Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746–53.PubMedCrossRef

10.

Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.PubMedCrossRef

11.

Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–71.PubMedCrossRef

12.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.PubMedCrossRef

13.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.PubMedCrossRef

14.

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRef

15.

Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, et al. Reprofiling metastatic samples for chromosome 9p and 14q aberrations as a strategy to overcome tumor heterogeneity in clear-cell renal cell carcinoma. Appl Immunohistochem Mol Morphol. 2017;25(1):39–43.PubMedCrossRef

16.

El-Mokadem I, Fitzpatrick J, Rai B, Cunningham J, Pratt N, Feming S, et al. Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies. Biomed Res Int. 2014;2014:521380.PubMedPubMedCentralCrossRef

17.

Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994;54(23):6078–82.PubMed

18.

NIH. Quality assessment tool for observational cohort and cross-sectional studies. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

19.

Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence, second edition. Br Med J Lond. 2000;24:45–56.

20.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

21.

Petrie A, Bulman JS, Osborn JF. Further statistics in dentistry. Part 8: systematic reviews and meta-analyses. Br Dent J. 2003;194:73–8.PubMedCrossRef

22.

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester: Wiley; 2009.CrossRef

23.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedPubMedCentralCrossRef

24.

El-Mokadem I, Kidd T, Pratt N, Fleming S, Nabi G. Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer. Oncotarget. 2016;7(45):73045–54.PubMedPubMedCentralCrossRef

25.

de Oliveira D, Dall’Oglio MF, Reis ST, Zerati M, Souza IC, Leite KR, et al. Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma. Urol Oncol. 2014;32(5):601–6.PubMedCrossRef

26.

El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, Cunningham J, Pratt N, et al. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery. Br J Cancer. 2014;111(7):1381–90.PubMedPubMedCentralCrossRef

27.

Antonelli A, Arrighi N, Tardanico R, Balzarini P, Zanotelli T, Corti S, et al. Prognostic value of cytogenetic analysis in clear cell renal carcinoma: a study on 131 patients with long-term follow-up. Anticancer Res. 2010;30(11):4705–9.PubMed

28.

Brunelli M, Eccher A, Gobbo S. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2008;21(1):1–6.PubMedCrossRef

29.

Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert RH, Jakse G, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res. 2003;63(19):6200–5.PubMed

30.

Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162–9.PubMedCrossRef

31.

La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010;116(20):4696–702.PubMedCrossRef

32.

Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, et al. D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer. 2011;117(18):4201–11.PubMedCrossRef

33.

Moch H, Presti JC Jr, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56(1):27–30.PubMed

34.

Schraml P, Muller D, Bednar R, et al. Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J Pathol. 2000;190:457–61.PubMedCrossRef

35.

Schraml P, Struckmann K, Bednar R, Gasser T, Sauter G, Mihatsch MJ, Moch H. CDKN2A mutation analysis, protein expression, and deletion mapping of chromosome 9p conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol. 2001;158(2):593–601.PubMedPubMedCentralCrossRef

36.

Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol. 2002;167(3):1464–8.PubMedCrossRef

37.

Sanjmyatav J, Junker K, Matthesetal S. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol. 2011;186(5):2078–83.PubMedCrossRef

38.

El-Mokadem I, Lim A, Kidd T, Garret K, Pratt N, Batty D, et al. Microsatellite alteration and immunohistochemical expression profile of chromosome 9p21 in patients with sporadic renal cell carcinoma following surgical resection. BMC Cancer. 2016;16:546.PubMedPubMedCentralCrossRef

39.

Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16(6):676–85.CrossRefPubMed

40.

Budczies J, Denkert C, Győrffy B, Schirmacher P, Stenzinger A, et al. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Med Genom. 2017;10(1):74.CrossRef

Titel: A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss
verfasst von: Vincenzo Di Nunno
Veronica Mollica
Matteo Brunelli
Lidia Gatto
Riccardo Schiavina
Michelangelo Fiorentino
Matteo Santoni
Rodolfo Montironi
Anna Caliò
Albino Eccher
Michele Milella
Guido Martignoni
Eugenio Brunocilla
Francesco Massari
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 5/2019
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-019-00414-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss